Author:
Bao Xiebing,Chi Jingyun,Zhu Yiwei,Yang Minfeng,Du Jiahui,Tang Zaixiang,Xu Xiaogang,Mao Genxiang,Wu Zhibing,Chen Jun,Hua Jingsheng,Xu Ting,Liu Song-Bai
Abstract
Abstract
Background
As a core member of the FA complex, in the Fanconi anemia pathway, FAAP24 plays an important role in DNA damage repair. However, the association between FAAP24 and patient prognosis in AML and immune infiltration remains unclear. The purpose of this study was to explore its expression characteristics, immune infiltration pattern, prognostic value and biological function using TCGA-AML and to verify it in the Beat AML cohort.
Methods
In this study, we examined the expression and prognostic value of FAAP24 across cancers using data from TCGA, TARGET, GTEx, and GEPIA2. To further investigate the prognosis in AML, development and validation of a nomogram containing FAAP24 were performed. GO/KEGG, ssGSEA, GSVA and xCell were utilized to explore the functional enrichment and immunological features of FAAP24 in AML. Drug sensitivity analysis used data from the CellMiner website, and the results were confirmed in vitro.
Results
Integrated analysis of the TCGA, TARGET and GTEx databases showed that FAAP24 is upregulated in AML; meanwhile, high FAAP24 expression was associated with poor prognosis according to GEPIA2. Gene set enrichment analysis revealed that FAAP24 is implicated in pathways involved in DNA damage repair, the cell cycle and cancer. Components of the immune microenvironment using xCell indicate that FAAP24 shapes an immunosuppressive tumor microenvironment (TME) in AML, which helps to promote AML progression. Drug sensitivity analysis showed a significant correlation between high FAAP24 expression and chelerythrine resistance. In conclusion, FAAP24 could serve as a novel prognostic biomarker and play an immunomodulatory role in AML.
Conclusions
In summary, FAAP24 is a promising prognostic biomarker in AML that requires further exploration and confirmation.
Funder
Jiangsu Higher Education Institution Innovative Research Team for Science and Technology
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference37 articles.
1. Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Hematol Oncol Clin N Am. 2010;24(1):35–63.
2. Welsh J. Acute Myeloid Leukemia Survival Rates and Outlook 2021. Available from: https://www.verywellhealth.com/acute-myeloid-leukemia-survival-rates-5208865.
3. Steffen B, Müller-Tidow C, Schwäble J, Berdel WE, Serve H. The molecular pathogenesis of acute myeloid leukemia. Crit Rev Oncol/Hematol. 2005;56(2):195–221.
4. Tan Y, Zheng L, Du Y, Zhong Q, Zhu Y, Liu ZML, Shuang, et al. Identification of the hub genes and pathways involved in acute myeloid leukemia using bioinformatics analysis. Medicine. 2020;99(35):e22047.
5. Donehower L, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M et al. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Reports. 2019;28:1370-84.e5.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献